AstraZeneca PLC
See purchases and sales reported by corporate insiders and members of Congress. These are disclosed transactions, not a list of everyone trading the stock.
Free to read. No brokerage connection required.
In the retrieved 180-day disclosure window, 2 filers reported purchases and 0 filers reported sales of AZN. A filer can appear in both groups. The transactions may have happened before they were disclosed.
Latest recorded disclosure:
Data retrieved 9/12/2026, 7:33:26 PM UTC. This is the retrieval time, not the date of each source document. Filings can be delayed, amended or awaiting processing.
Amounts and owners belong to individual reported transactions. Congressional ranges are preserved; they are not exact dollar totals.
Reported purchase
20.233 shares at $160.57 reported per share
See Remarks
Plan unknown. The filing does not mark an advance trading plan. This alone does not confirm an unplanned trade.
Original filing ↗Reported purchase
$15,001.00–$50,000.00 reported range
Senate · OK · Reported owner: self
Reported purchase
$1,001.00–$15,000.00 reported range
Senate · OK · Reported owner: self
A filing records a transaction and any reported context. It does not establish the seller's motive or predict the stock's return. Check the source, ownership and trading-plan information before drawing a conclusion.
The transaction date describes when the reported trade happened; the disclosure date describes when the report entered the public record. Form 4 transactions are generally reported within two business days. Congressional reports use different deadlines and can arrive weeks after trading. See the SEC's explanation.
Verified trading-plan information was not established for the transaction. An unchecked box alone does not prove an unplanned trade, and a filing-wide statement may not describe every row. Trading-plan labels here apply to corporate insiders, not congressional reports.
Educational disclosure research. It is not a complete view of anyone's holdings, a live trade alert or an investment recommendation.